In non-small cell lung cancer (NSCLC), CCL2 reduces E-cadherin levels and upregulates vimentin, MMP-2 and MMP-9 protein levels through PI3K/Akt/mTOR to activate EMT (196). This evidence concerns the gene CCL2 and non-small cell lung carcinoma.